Galecto Stock News

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for

BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced t

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified

Galecto press release (GLTO): FY GAAP EPS of -$2.05 beats by $0.08.Cash, cash equivalents, and investments as of December 31, 2021 were approximately $109.2 million.

Continued pipeline progress with three potentially first-in-class product candidates

During the last session, Galecto Inc. (NASDAQ:GLTO)s traded shares were 0.91 million. At the end of the trading day, the stocks price was $2.82, reflecting an intraday gain of 22.61% or $0.52. The 52-week high for the GLTO share is $16.41, that puts it down -481.91 from that peak though still a striking 21.28% gain Boom Or Bust: Where Does Galecto Inc. (NASDAQ: GLTO) Stock Go From Here? Read More »

Brokerages predict that Galecto, Inc. (NASDAQ:GLTO) will announce ($0.56) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Galectos earnings. The company is expected to issue its next earnings results on Monday, April 4th. According to Zacks, analysts expect that Galecto will report full year earnings of ($2.12) []

Zacks Investment Research upgraded shares of Galecto (NASDAQ:GLTO) from a hold rating to a buy rating in a report published on Friday, Zacks.com reports. Zacks Investment Research currently has $2.75 target price on the stock. According to Zacks, Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on []

Brokerages predict that Galecto, Inc. (NASDAQ:GLTO) will post earnings of ($0.56) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Galectos earnings. The business is scheduled to report its next quarterly earnings results on Monday, April 4th. On average, analysts expect that Galecto will report full year []

Zacks Investment Research upgraded shares of Galecto (NASDAQ:GLTO) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. They currently have $3.25 target price on the stock. According to Zacks, Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on []

Galecto, Inc. (NASDAQ:GLTO) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 55,800 shares, a drop of 21.8% from the October 31st total of 71,400 shares. Approximately 0.6% of the shares of the company are sold short. Based on an []

Geode Capital Management LLC purchased a new position in Galecto, Inc. (NASDAQ:GLTO) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 74,720 shares of the companys stock, valued at approximately $378,000. Other hedge funds also recently made changes to their positions in [] The post Geode Capital Management LLC Makes New $378,000 Investment in Galecto, Inc. (NASDAQ:GLTO) appeared first on ETF Daily News .

Brokerages expect that Galecto, Inc. (NASDAQ:GLTO) will post ($0.56) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Galectos earnings. The business is scheduled to issue its next quarterly earnings results on Monday, April 4th. According to Zacks, analysts expect that Galecto will report full year earnings []

BeiGene (NASDAQ:BGNE) and Galecto (NASDAQ:GLTO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of recent recommendations and price targets for BeiGene and Galecto, as reported […]